Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tretinoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 5/20 | 1.00 |
| ▸ | RARA known ✓ | P10276 | 4/20 | 1.00 |
| ▸ | RARB known ✓ | P10826 | 4/20 | 1.00 |
| ▸ | RARG known ✓ | P13631 | 4/20 | 1.00 |
| ▸ | RXRB known ✓ | P28702 | 2/20 | 1.00 |
| ▸ | RXRG known ✓ | P48443 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | RORC | P51449 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tretinoin SCHEMBL3146 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL9123793 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL8399912 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL7846921 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982760 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL38299 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982761 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Alitretinoin SCHEMBL5331051 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL18667 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL20603086 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6687 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589189-B2 | Use of retinoic acid receptor (RAR) agonists for reversing, preventing, or delaying calcification of aortic valve | INSERM (INSTITUTE NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | claimed |
| US-12582593-B2 | Oral care compositions for gum health | THE PROCTER & GAMBLE COMPANY (US) | 2026-03-24 | — | — | US | claimed |
| EP-4037672-B1 | RETINOIC ACID RECEPTOR (RAR) AGONISTS FOR REVERSING, PREVENTING, OR DELAYING CALCIFICATION OF AORTIC VALVE | INST NAT SANTE RECH MED (FR) | 2026-03-11 | — | — | EP | claimed |
| EP-4605517-A1 | AN IN VITRO METHOD FOR PRODUCING A 3D-STRUCTURE OF CELLS | Universiteit Maastricht (NL) | 2025-08-27 | — | — | EP | claimed |
| US-20250115674-A1 | ANTIBODY TARGETING B CELL MATURATION ANTIGEN AND RELATED PRODUCTS THEREOF AND MEDICAL APPLICATIONS | Beijing Gene MiNK Biotechnology CO.LTD (CN) | 2025-04-10 | — | — | US | claimed |
| EP-4110270-B1 | ORAL CARE COMPOSITIONS FOR GUM HEALTH | PROCTER & GAMBLE (US) | 2025-04-09 | — | — | EP | claimed |
| US-12268673-B2 | Anhydrous compositions of mTOR inhibitors and methods of use | PALVELLA THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| CN-119548644-A | Pharmaceutical composition and preparation method and application thereof | 四川大学 | 2025-03-04 | — | — | CN | claimed |
| WO-2025027331-A1 | TREATMENT OF NEUROBLASTOMA | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-02-06 | — | — | WO | claimed |
| EP-4434551-A1 | METHOD FOR DIAGNOSING AND TREATING NIS-EXPRESSING CARCINOMAS AND METASTASES | NUSKE, Andreas (DE) | 2024-09-25 | — | — | EP | claimed |
| EP-0219208-B1 | SUBSTAINED-RELEASE FORMULATION CONTAINING AN AMINO ACID POLYMER | BAUSCH & LOMB INCORPORATED (US) | 1992-06-24 | — | — | EP | claimed |
| EP-0443413-A1 | Pharmaceutical composition having depigmentating and antiphotoaging activity | Schering Spa (IT) | 1991-08-28 | — | — | EP | claimed |
| US-5021404-A | Angiostatic collagen modulators | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1991-06-04 | — | — | US | claimed |
| EP-0397774-A1 | FORMULATION AND USE OF RETINOIDS IN TREATMENT OF CANCER AND OTHER DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-11-22 | — | — | EP | claimed |
| US-4931279-A | Sustained release formulation containing an ion-exchange resin | BAUSCH & LOMB INCORPORATED (US) | 1990-06-05 | — | — | US | claimed |
| WO-1989006977-A1 | FORMULATION AND USE OF RETINOIDS IN TREATMENT OF CANCER AND OTHER DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-08-10 | — | — | WO | claimed |
| US-4837213-A | PARAFFIN OIL, FATTY ACID ALAKYL ESTER AND POLYVINYLDIMETHYL SILOXANE-TYPE ELASTOMERIC SILICONE | CENTRE INTERNATINAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1989-06-06 | — | — | US | claimed |
| US-4668506-A | Sustained-release formulation containing and amino acid polymer | BAUSCH & LOMB INCORPORATED (US) | 1987-05-26 | — | — | US | claimed |
| EP-0219207-A2 | Sustained-release formulation comprising a hydrophobic polymer system | BAUSCH & LOMB INCORPORATED (US) | 1987-04-22 | — | — | EP | claimed |
| EP-0219208-A2 | Substained-release formulation containing an amino acid polymer | BAUSCH & LOMB INCORPORATED (US) | 1987-04-22 | — | — | EP | claimed |